Ratings by Raymond James (Andrew Cooper)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/28/2024 | Myriad Genetics | MYGN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/20/2024 | Natera | NTRA | Downgrade | Outperform (Strong Buy) |
70.01 (91.28) |
30.38% | Details | |
| 2/14/2024 | Quidel Corp. | QDEL | Downgrade | Outperform (Strong Buy) |
66.77 (39.69) |
-40.56% | Details | |
| 2/1/2024 | Revvity Inc | RVTY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2023 | Guardant Health | GH | Upgrade | Outperform (Market Perform) |
22.49 (17.16) |
-23.7% | Details | |
| 11/13/2023 | Natera | NTRA | Upgrade | Strong Buy (Outperform) |
45.39 (91.28) |
101.1% | Details | |
| 10/18/2023 | Hologic | HOLX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/18/2023 | Thermo Fisher Scientific | TMO | Maintain | Outperform (N/A) |
|
Details | ||
| 10/18/2023 | Revvity Inc | RVTY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/18/2023 | Danaher | DHR | Maintain | Outperform (N/A) |
|
Details | ||
| 8/28/2023 | Lumiradx Ltd. | LMDX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/15/2023 | CareDx, Inc | CDNA | Upgrade | Outperform (Market Perform) |
8.90 (7.56) |
-15.06% | Details | |
| 7/26/2023 | Danaher | DHR | Maintain | Outperform (N/A) |
|
Details | ||
| 7/19/2023 | Cytek Biosciences Inc | CTKB | New Coverage | Market Perform (N/A) |
9.00 (5.63) |
-37.44% | Details | |
| 7/19/2023 | Thor Industries Inc. | THO | New Coverage | Outperform (N/A) |
109.23 (100.75) |
-7.76% | Details | |
| 7/19/2023 | Danaher | DHR | New Coverage | Outperform (N/A) |
237.76 (245.80) |
3.38% | Details | |
| 7/19/2023 | Revvity Inc | RVTY | New Coverage | Outperform (N/A) |
121.00 (102.09) |
-15.63% | Details | |
| 7/19/2023 | Azenta, Inc. | AZTA | New Coverage | Market Perform (N/A) |
44.99 (51.50) |
14.47% | Details | |
| 5/17/2023 | Lumiradx Ltd. | LMDX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/16/2023 | NeoGenomics | NEO | Downgrade | Market Perform (Outperform) |
12.84 (13.85) |
7.87% | Details | |
| 5/15/2023 | Invitae Corporation | NVTA | Downgrade | Underperform (Market Perform) |
1.39 (0.02) |
-98.56% | Details | |
| 4/6/2023 | Lumiradx Ltd. | LMDX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2023 | Natera | NTRA | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/3/2023 | Myriad Genetics | MYGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/3/2023 | CareDx, Inc | CDNA | Downgrade | Market Perform (Outperform) |
16.00 (7.56) |
-52.75% | Details | |
| 2/23/2023 | Neogenomics | NEO | Maintain | Outperform (N/A) |
|
Details | ||
| 1/31/2023 | CareDx, Inc | CDNA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/18/2023 | Myriad Genetics | MYGN | Upgrade | Outperform (Market Perform) |
18.67 (17.98) |
-3.7% | Details | |
| 1/18/2023 | Natera | NTRA | Upgrade | Outperform (Market Perform) |
41.82 (91.28) |
118.27% | Details | |
| 1/18/2023 | Exact Sciences | EXAS | Downgrade | Market Perform (Outperform) |
68.96 (58.79) |
-14.75% | Details | |
| 1/18/2023 | Veracyte, Inc | VCYT | Downgrade | Market Perform (Outperform) |
26.62 (19.48) |
-26.82% | Details | |
| 11/8/2022 | Haemonetics | HAE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/31/2022 | Avantor Inc. | AVTR | Maintain | Outperform (N/A) |
|
Details | ||
| 8/19/2022 | Lumiradx Ltd. | LMDX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/10/2022 | Haemonetics | HAE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/3/2022 | Exact Sciences | EXAS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/1/2022 | Avantor Inc. | AVTR | Maintain | Outperform (N/A) |
|
Details | ||
| 7/21/2022 | Invitae Corporation | NVTA | Downgrade | Market Perform (Outperform) |
2.21 (0.02) |
-99.1% | Details | |
| 5/12/2022 | Lumiradx Ltd. | LMDX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/11/2022 | Haemonetics | HAE | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2022 | Quidel Corp. | QDEL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/4/2022 | Invitae Corporation | NVTA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/4/2022 | Veracyte, Inc | VCYT | Maintain | Outperform (N/A) |
|
Details | ||
| 4/27/2022 | Exact Sciences | EXAS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2022 | Veracyte, Inc | VCYT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2022 | Invitae Corporation | NVTA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/25/2022 | CareDx, Inc | CDNA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/23/2022 | Neogenomics | NEO | Maintain | Outperform (N/A) |
|
Details | ||
| 2/23/2022 | Exact Sciences | EXAS | Maintain | Outperform (N/A) |
|
Details | ||
| 2/22/2022 | Quidel Corp. | QDEL | Upgrade | Strong Buy (Outperform) |
97.84 (39.69) |
-59.43% | Details | |
| 2/7/2022 | Avantor Inc. | AVTR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2021 | Invitae Corporation | NVTA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2021 | Exact Sciences | EXAS | Downgrade | Outperform (Strong Buy) |
97.44 (58.79) |
-39.67% | Details | |
| 11/1/2021 | Avantor Inc. | AVTR | Maintain | Outperform (N/A) |
|
Details | ||
| 10/29/2021 | CareDx, Inc | CDNA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/25/2021 | Lumiradx Ltd. | LMDX | New Coverage | Outperform (N/A) |
8.56 (0.02) |
-99.77% | Details | |
| 10/14/2021 | Neogenomics | NEO | Upgrade | Outperform (Market Perform) |
42.00 (13.85) |
-67.02% | Details | |
| 9/22/2021 | OraSure Technologies | OSUR | Downgrade | Market Perform (Outperform) |
12.80 (5.26) |
-58.91% | Details | |
| 8/30/2021 | Avantor Inc. | AVTR | New Coverage | Outperform (N/A) |
39.28 (25.15) |
-35.97% | Details | |
| 8/17/2021 | Haemonetics | HAE | New Coverage | Outperform (N/A) |
61.14 (87.66) |
43.38% | Details | |
| 8/4/2021 | OraSure Technologies | OSUR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/28/2021 | Veracyte, Inc | VCYT | Maintain | Outperform (N/A) |
|
Details | ||
| 6/28/2021 | Quidel Corp. | QDEL | Maintain | Outperform (N/A) |
|
Details | ||
| 6/28/2021 | OraSure Technologies | OSUR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/28/2021 | CareDx, Inc | CDNA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 6/15/2021 | Myriad Genetics | MYGN | New Coverage | Market Perform (N/A) |
29.94 (17.98) |
-39.95% | Details | |
| 6/15/2021 | Guardant Health | GH | New Coverage | Market Perform (N/A) |
123.77 (17.16) |
-86.14% | Details | |
| 6/15/2021 | Natera | NTRA | New Coverage | Market Perform (N/A) |
103.75 (91.28) |
-12.02% | Details | |
| 6/15/2021 | Veracyte, Inc | VCYT | New Coverage | Outperform (N/A) |
37.25 (19.48) |
-47.7% | Details | |
| 6/15/2021 | Exact Sciences | EXAS | New Coverage | Strong Buy (N/A) |
125.01 (58.79) |
-52.97% | Details | |
| 6/15/2021 | Invitae Corporation | NVTA | New Coverage | Outperform (N/A) |
31.22 (0.02) |
-99.94% | Details | |
| 6/2/2021 | Progenity Inc. | PROG | Downgrade | Market Perform (Outperform) |
2.86 (0.88) |
-69.23% | Details | |
| 5/14/2021 | Progenity Inc. | PROG | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2021 | Quidel Corp. | QDEL | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2021 | OraSure Technologies | OSUR | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2021 | CareDx, Inc | CDNA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/11/2021 | Quidel Corp. | QDEL | Maintain | Outperform (N/A) |
|
Details | ||
| 2/25/2021 | CareDx, Inc | CDNA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/25/2021 | Neogenomics | NEO | Downgrade | Market Perform (Outperform) |
52.99 (13.85) |
-73.86% | Details | |
| 2/19/2021 | Quidel Corp. | QDEL | Maintain | Outperform (N/A) |
|
Details | ||
| 1/22/2021 | Quidel Corp. | QDEL | Upgrade | Outperform (Market Perform) |
212.58 (97.84) |
-53.97% | Details | |
| 12/10/2020 | CareDx, Inc | CDNA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/10/2020 | Progenity Inc. | PROG | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2020 | OraSure Technologies | OSUR | Upgrade | Outperform (Market Perform) |
19.58 (5.26) |
-73.14% | Details | |
| 6/19/2020 | CNDA | Maintain | Strong Buy (N/A) |
|
Details | |||
| 3/2/2020 | Neogenomics | NEO | Maintain | Outperform (N/A) |
|
Details |
